Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
XDK.6ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
XDK.6NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-19646.7China
XDK.6NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
LL.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
LL.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-19646.7China
LL.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
GS.8ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
GS.8NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
GS.8NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
GE.1.4ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
GE.1.4NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
GE.1.4NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
XBB.1.5.93ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
XBB.1.5.93NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
XBB.1.5.93NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
FL.2.3.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
FL.2.3.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
FL.2.3.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
FL.4.8ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
FL.4.8NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
FL.4.8NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
EG.5.1.18ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
EG.5.1.18NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
EG.5.1.18NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
HK.4ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
HK.4NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
HK.4NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
GM.3ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
GM.3NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
GM.3NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
FL.13.2ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
FL.13.2NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
FL.13.2NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
GV.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
GV.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
GV.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
EG.5ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
EG.5NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
EG.5NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
XBB.1.5.25ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
XBB.1.5.25NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
XBB.1.5.25NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BN.1.2.6ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BN.1.2.6NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BN.1.2.6NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
XBB.1.16.26ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
XBB.1.16.26NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
XBB.1.16.26NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
GJ.3ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
GJ.3NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used